Surface Oncology, Inc. (NASDAQ:SURF) saw unusually large options trading activity on Monday. Traders purchased 7,030 call options on the company. This represents an increase of 1,598% compared to the typical daily volume of 414 call options.
Surface Oncology stock opened at $7.33 on Tuesday. The company’s 50-day moving average price is $7.84 and its two-hundred day moving average price is $9.17. The stock has a market cap of $318.29 million, a price-to-earnings ratio of -11.11 and a beta of 2.09. Surface Oncology has a 52 week low of $2.39 and a 52 week high of $14.40. The company has a current ratio of 7.94, a quick ratio of 7.94 and a debt-to-equity ratio of 0.17.
Surface Oncology (NASDAQ:SURF) last released its earnings results on Monday, March 8th. The company reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $1.43. The firm had revenue of $87.57 million during the quarter, compared to analyst estimates of $85.00 million. Research analysts expect that Surface Oncology will post 0.1 earnings per share for the current fiscal year.
A number of institutional investors have recently modified their holdings of the business. Schonfeld Strategic Advisors LLC grew its stake in shares of Surface Oncology by 40.6% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 102,100 shares of the company’s stock worth $704,000 after purchasing an additional 29,500 shares during the last quarter. Morgan Stanley lifted its position in shares of Surface Oncology by 1,138.7% during the 4th quarter. Morgan Stanley now owns 1,073,129 shares of the company’s stock valued at $9,916,000 after acquiring an additional 986,495 shares during the last quarter. Optimum Investment Advisors bought a new stake in shares of Surface Oncology during the 4th quarter worth $28,000. GSA Capital Partners LLP acquired a new stake in shares of Surface Oncology during the fourth quarter worth $247,000. Finally, Quantitative Systematic Strategies LLC lifted its holdings in shares of Surface Oncology by 19.7% during the fourth quarter. Quantitative Systematic Strategies LLC now owns 28,182 shares of the company’s stock valued at $260,000 after purchasing an additional 4,633 shares during the last quarter. Hedge funds and other institutional investors own 51.97% of the company’s stock.
A number of research analysts recently issued reports on the company. TheStreet upgraded Surface Oncology from a “d” rating to a “c-” rating in a research report on Monday, April 19th. Jonestrading reissued a “buy” rating and set a $18.00 price target on shares of Surface Oncology in a report on Sunday, April 11th. Zacks Investment Research cut shares of Surface Oncology from a “hold” rating to a “sell” rating in a report on Thursday, April 29th. Finally, Robert W. Baird reissued a “buy” rating and set a $14.00 target price on shares of Surface Oncology in a research note on Monday, March 22nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $13.00.
About Surface Oncology
Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 (IgG4) monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; SRF813 targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8 to deplete immuno-suppressive cells.
Read More: What are municipal bonds?
Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.